Retinopathy of Prematurity Ophthalmologic Approach Medication

Updated: Oct 04, 2018
  • Author: Mounir Bashour, MD, PhD, CM, FRCSC, FACS; Chief Editor: Donny W Suh, MD, MBA, FAAP, FACS  more...
  • Print

Medication Summary

In a prospective study by Repka et al, surfactant has not been found to lower the incidence of ROP. [21]

A study by Wu et al examined the use of bevacizumab to treat ROP. [22] Among the 27 patients (18 male, 9 female) in the study, 49 eyes were included. The study found that bevacizumab was effective and well-tolerated in some cases of ROP, most notably in stage 3. However, the study did note that complications from bevacizumab were possible in pediatric patients.

A study by Mintz-Hittner et al examined the use of bevacizumab to treat ROP in 150 infants. [23] The study found that monotherapy with bevacizumab showed a significant treatment benefit in zone I ROP (P=0.003) but not in zone II ROP (P=0.27). However, the study size was too small to assess safety. Long-term studies are still necessary.